TRML
Tourmaline Bio, Inc.Company Information
- Company Name
- Tourmaline Bio, Inc.
- CIK
- CIK0001827506
- Category
- <br>Emerging growth company
- Ticker: Exchange
- TRML: None
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- TRML
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-21
- Last sale
- 2023-06-14
- Shares purchased (TTM)
- 142,300
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 21,398,842
- Shares outstanding
- 25,755,000
- Ownership
- 83.09%
Earnings Market Reaction
- Filing date
- —
- Price on filing date
- —
- 1-month reaction
- —
- 3-month reaction
- —
Balance Sheet
Values in millions ($)| Line item | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 31 | 35 | 31 | 35 | 70 | 98 | 141 | 78 | 87 | 4 | 8 | 18 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | - | 80 | 134 | 142 | 168 | 175 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 249 | 258 | 269 | 294 | 298 | 300 | 209 | 151 | 156 | 169 | 8 | 198 | ||||||
| Available For Sale Securities Debt Securities Current | 208 | 214 | 228 | 247 | 219 | 195 | 62 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 10 | 9 | 11 | 12 | 9 | 7 | 6 | 4 | 4 | 3 | 0 | 4 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 5 | ||||||
| Assets Held In Trust Noncurrent | - | - | - | - | - | - | - | 0 | 2 | - | - | - | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 17 | 26 | 37 | 32 | 45 | 57 | 0 | - | - | - | - | - | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | ||||||
| Restricted Cash | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Other Assets Noncurrent | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 269 | 287 | 309 | 328 | 345 | 359 | 210 | 151 | 159 | 173 | 9 | 207 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 0 | 3 | 3 | 0 | 2 | ||||||
| Accrued Liabilities Current | 7 | 5 | 5 | 5 | 4 | 3 | 4 | 7 | 6 | 6 | 1 | 6 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 10 | 8 | 9 | 7 | 6 | 5 | 5 | 8 | 10 | 10 | 1 | 9 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 10 | 8 | 9 | 7 | 7 | 5 | 5 | 8 | 11 | 11 | 2 | 12 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | - | - | - | 27 | - | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 259 | 280 | 300 | 321 | 338 | 354 | 205 | -47 | -43 | -27 | -20 | 195 | ||||||
| Additional Paid In Capital | 440 | 438 | 435 | 433 | 432 | 430 | 267 | 352 | 351 | 349 | 0 | 342 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -0 | -0 | -0 | 0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -181 | -158 | -135 | -113 | -93 | -75 | -62 | -209 | -202 | -187 | -20 | -146 | ||||||
| Liabilities And Stockholders Equity | 269 | 287 | 309 | 328 | 345 | 359 | 210 | 151 | 159 | 173 | 9 | 207 | ||||||
| Nonvoting Common Stock | 0 | 10 | 10 | 0 | 0 | 10 | 10 | 0 | 0 | 10 | 10 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | - | - | 0 | - | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | - | - | - | 27 | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 0 | - | - | - | 27 | - | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | - | - | - | 27 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 140 | 50 | 140 | ||||||
| Common Stock Shares Issued | 26 | 26 | 26 | 26 | 26 | 26 | 20 | 20 | 4 | 4 | 1 | 4 | ||||||
| Shares Outstanding | 26 | 26 | 26 | 26 | 26 | 26 | 20 | 20 | 4 | 4 | 1 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTourmaline Bio, Inc. (TRML) — SEC Financial Statements & Analysis
Tourmaline Bio, Inc. (TRML) is a biological products, (no diagnostic substances) company, incorporated in DE. Tourmaline Bio, Inc. trades on None as: TRML. Tourmaline Bio, Inc. (TRML)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-13. Based on that filing, On profitability, Tourmaline Bio, Inc. posts a Return on Equity (ROE) of -29.62%, a Return on Assets (ROA) of -28.81%, and a Return on Invested Capital (ROIC) of -41.36%. Per share, it reports EPS of $-3.44, diluted EPS of $-3.44, free cash flow per share of $-3.35, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 74.57% year-over-year and EPS growth of 74.36% year-over-year. On the balance sheet, it maintains a current ratio of 24.68x, a quick ratio of 23.70x, working capital of $239.01M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, an interest coverage ratio of -31.83x, free cash flow of $-86.30M (TTM), and net debt of $-31.65M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-3.44
- ROE TTM
- -29.62%
- ROA TTM
- -28.81%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-86.30M
Data as of 2025-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Tourmaline Bio, Inc. in?
Tourmaline Bio, Inc. (TRML) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does TRML trade on?
Tourmaline Bio, Inc. (TRML) trades on the None.
Where is Tourmaline Bio, Inc. incorporated?
Tourmaline Bio, Inc. is incorporated in DE.
When was Tourmaline Bio, Inc. (TRML)'s most recent SEC filing?
Tourmaline Bio, Inc. (TRML)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-13.
What is TRML's EPS (earnings per share)?
Tourmaline Bio, Inc. (TRML)'s trailing twelve month EPS is $-3.44 as of 2025-06-30.
What is TRML's ROE (return on equity)?
Tourmaline Bio, Inc. (TRML)'s trailing twelve month Return on Equity (ROE) is -29.62% as of 2025-06-30.
What is TRML's ROA (return on assets)?
Tourmaline Bio, Inc. (TRML)'s trailing twelve month Return on Assets (ROA) is -28.81% as of 2025-06-30.
What is TRML's ROIC (return on invested capital)?
Tourmaline Bio, Inc. (TRML)'s trailing twelve month Return on Invested Capital (ROIC) is -41.36% as of 2025-06-30.